These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16597603)

  • 1. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
    van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM
    Blood; 2006 Apr; 107(8):3415-6. PubMed ID: 16597603
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
    Awan FT; Osman S; Kochuparambil ST; Gibson L; Remick SC; Abraham J; Craig M; Jillella A; Hamadani M
    Bone Marrow Transplant; 2012 Jan; 47(1):146-8. PubMed ID: 21358681
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
    Kröger N; Zabelina T; Ayuk F; Atanackovic D; Schieder H; Renges H; Zander A
    Exp Hematol; 2006 Jun; 34(6):770-5. PubMed ID: 16728282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
    Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; La Sala A; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'Olio M; Bodenizza C; Greco MM; Carella AM; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
    Leuk Res; 2006 Mar; 30(3):283-5. PubMed ID: 16111749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of the high-dose therapy in the area of new drugs.
    Schmitt S; Bertsch U; Hose D; Goldschmidt H
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():90-4. PubMed ID: 22352189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
    Krüger WH; Kiefer T; Schüler F; Lotze C; Busemann C; Dölken G
    Onkologie; 2007 Apr; 30(4):193-5. PubMed ID: 17396042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontline treatment of multiple myeloma.
    Fonseca R
    Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplants for the elderly in myeloma.
    Morgan GJ
    Blood; 2013 Aug; 122(8):1332-4. PubMed ID: 23970352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
    El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
    Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Moreau P; Avet-Loiseau H; Facon T; Attal M; Tiab M; Hulin C; Doyen C; Garderet L; Randriamalala E; Araujo C; Lepeu G; Marit G; Caillot D; Escoffre M; Lioure B; Benboubker L; Pégourié B; Kolb B; Stoppa AM; Fuzibet JG; Decaux O; Dib M; Berthou C; Chaleteix C; Sebban C; Traullé C; Fontan J; Wetterwald M; Lenain P; Mathiot C; Harousseau JL
    Blood; 2011 Nov; 118(22):5752-8; quiz 5982. PubMed ID: 21849487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
    Dytfeld D; Matuszak M; Lewandowski K; Komarnicki M
    Ann Hematol; 2008 Mar; 87(3):253-4. PubMed ID: 17955241
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
    Montefusco V; Spina F; Patriarca F; Offidani M; Bruno B; Montanari M; Mussetti A; Sperotto A; Scortechini I; Dodero A; Fanin R; Valagussa P; Corradini P
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):424-8. PubMed ID: 23142330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
    Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A;
    Blood; 2012 Jul; 120(1):9-19. PubMed ID: 22498745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
    Kuroda J; Kobayashi T; Tsutsumi Y; Yamamoto M; Ohshiro M; Sasaki N; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Nakayama R; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Taniwaki M
    Int J Hematol; 2010 Nov; 92(4):669-72. PubMed ID: 20978877
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.